<DOC>
	<DOCNO>NCT00696137</DOCNO>
	<brief_summary>This study design provide continued access BEMA Fentanyl subject previously participate FEN-202 wish continue use BEMA Fentanyl treatment breakthrough cancer pain .</brief_summary>
	<brief_title>Long-term Extension Study BEMAâ„¢ Fentanyl</brief_title>
	<detailed_description />
	<mesh_term>Fentanyl</mesh_term>
	<criteria>1. previously qualify participate study FEN202 least 2 week , 2. wish continue use BEMA Fentanyl treatment breakthrough pain episode , 3. provide sign informed consent screen prior study procedure . 1. develop new medical condition initial enrollment FEN202 , opinion investigator , would preclude safe appropriate use BEMA Fentanyl participation study , 2. evidence improper use study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>